Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes

Diabetologia

Volumn 58, Issue 7, 2015, Pages 1656-1667

  Oguiza, Ainhoa ^a,b   Recio, Carlota ^a,b   Lazaro, Iolanda ^a   Mallavia, Beñat ^a   Blanco, Julia ^c   Egido, Jesus ^a,b   Gomez Guerrero, Carmen ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Atherosclerosis; Diabetes; Inflammation; Nephropathy; Nuclear factor B; Peptide

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN TYPE 1; FIBRONECTIN; GAMMA INTERFERON; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; KIDNEY INJURY MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; NEMO PROTEIN, MOUSE; PEPTIDE; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; GENE EXPRESSION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SIGNAL TRANSDUCTION; TH1 CELL; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HELPER CELL; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; I-KAPPA B KINASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MICE; MICE, KNOCKOUT; NF-KAPPA B; PEPTIDES; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84931562791     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3596-6     Document Type: Article

References (49)

1. Nathan DM (1993) Long-term complications of diabetes mellitus. N Engl J Med 328:1676–1685
2. De CS, Bacci S, Piras GP et al (1997) High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia 40:1191–1196
3. Rask-Madsen C, King GL (2013) Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab 17:20–33
4. Williams MD, Nadler JL (2007) Inflammatory mechanisms of diabetic complications. Curr Diab Rep 7:242–248
5. Nilsson J, Bengtsson E, Fredrikson GN, Bjorkbacka H (2008) Inflammation and immunity in diabetic vascular complications. Curr Opin Lipidol 19:519–524
6. Beinke S, Ley SC (2004) Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 382:393–409
7. Hayden MS, Ghosh S (2011) NF-κB in immunobiology. Cell Res 21:223–244
8. Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006:re13
9. Hinz M, Scheidereit C (2014) The IκB kinase complex in NF-kappaB regulation and beyond. EMBO Rep 15:46–61
10. May MJ, D’Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S (2000) Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 289:1550–1554
11. Brosius FC, Khoury CC, Buller CL, Chen S (2010) Abnormalities in signaling pathways in diabetic nephropathy. Expert Rev Endocrinol Metab 5:51–64
12. Mezzano S, Aros C, Droguett A et al (2004) NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19:2505–2512
13. Schmid H, Boucherot A, Yasuda Y et al (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993–3003
14. Yi B, Hu X, Zhang H et al (2014) Nuclear NF-kappaB p65 in peripheral blood mononuclear cells correlates with urinary MCP-1, RANTES and the severity of type 2 diabetic nephropathy. PLoS One 9:e99633
15. Baker RG, Hayden MS, Ghosh S (2011) NF-kappaB, inflammation, and metabolic disease. Cell Metab 13:11–22
16. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB (2002) Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 13:894–902
17. Gao P, Wu X, Shui H, Jia R (2013) Fluvastatin inhibits high glucose-induced nuclear factor kappa B activation in renal tubular epithelial cells. J Nephrol 26:289–296
18. Gupta SC, Sundaram C, Reuter S, Aggarwal BB (2010) Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799:775–787
19. Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A (2012) Inhibitory kappa B Kinases as targets for pharmacological regulation. Br J Pharmacol 165:802–819
20. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J (2014) Therapeutic approaches to diabetic nephropathy—beyond the RAS. Nat Rev Nephrol 10:325–346
21. Lopez-Parra V, Mallavia B, Lopez-Franco O et al (2012) Fcγ receptor deficiency attenuates diabetic nephropathy. J Am Soc Nephrol 23:1518–1527
22. Hernandez-Vargas P, Lopez-Franco O, Sanjuan G et al (2005) Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J Am Soc Nephrol 16:1673–1683
23. Lopez-Franco O, Hernandez-Vargas P, Ortiz-Munoz G et al (2006) Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 26:1864–1870
24. Recio C, Oguiza A, Lazaro I, Mallavia B, Egido J, Gomez-Guerrero C (2014) Suppressor of cytokine signaling 1-derived peptide inhibits janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice. Arterioscler Thromb Vasc Biol 34:1953–1960
25. Lopez-Franco O, Suzuki Y, Sanjuan G et al (2002) Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol 161:1497–1505
26. Baima ET, Guzova JA, Mathialagan S et al (2010) Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides. J Biol Chem 285:13498–13506
27. Lassila M, Seah KK, Allen TJ et al (2004) Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15:2125–2138
28. Hegazy DM, O'Reilly DA, Yang BM, Hodgkinson AD, Millward BA, Demaine AG (2001) NFκB polymorphisms and susceptibility to type 1 diabetes. Genes Immun 2:304–308
29. Romzova M, Hohenadel D, Kolostova K et al (2006) NFkappaB and its inhibitor IκB in relation to type 2 diabetes and its microvascular and atherosclerotic complications. Hum Immunol 67:706–713
30. Lamhamedi-Cherradi SE, Zheng S, Hilliard BA et al (2003) Transcriptional regulation of type I diabetes by NF-kappa B. J Immunol 171:4886–4892
31. Eldor R, Yeffet A, Baum K et al (2006) Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci U S A 103:5072–5077
32. Wunderlich FT, Luedde T, Singer S et al (2008) Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc Natl Acad Sci U S A 105:1297–1302
33. Kumar A, Negi G, Sharma SS (2012) Suppression of NF-kappaB and NF-kappaB regulated oxidative stress and neuroinflammation by BAY 11-7082 (IκB phosphorylation inhibitor) in experimental diabetic neuropathy. Biochimie 94:1158–1165
34. Huang H, Xin H, Liu X et al (2012) Novel anti-diabetic effect of SCM-198 via inhibiting the hepatic NF-kappaB pathway in db/db mice. Biosci Rep 32:185–195
35. Dave SH, Tilstra JS, Matsuoka K et al (2007) Amelioration of chronic murine colitis by peptide-mediated transduction of the IκB kinase inhibitor NEMO binding domain peptide. J Immunol 179:7852–7859
36. Tas SW, de Jong EC, Hajji N et al (2005) Selective inhibition of NF-kappaB in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization. Eur J Immunol 35:1164–1174
37. Dasgupta S, Jana M, Zhou Y, Fung YK, Ghosh S, Pahan K (2004) Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J Immunol 173:1344–1354
38. Jimi E, Aoki K, Saito H et al (2004) Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10:617–624
39. di Meglio P, Ianaro A, Ghosh S (2005) Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 52:951–958
40. Ankermann T, Reisner A, Wiemann T, Krams M, Kohler H, Krause MF (2005) Topical inhibition of nuclear factor-kappaB enhances reduction in lung edema by surfactant in a piglet model of airway lavage. Crit Care Med 33:1384–1391
41. Reay DP, Yang M, Watchko JF et al (2011) Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis 43:598–608
42. Habineza NG, Gaurnier-Hausser A, Patel R et al (2014) A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B cell like diffuse large B cell lymphoma. PLoS One 9:e95404
43. Pamukcu B, Lip GY, Shantsila E (2011) The nuclear factor–kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res 128:117–123
44. Gomez-Guerrero C, Mallavia B, Egido J (2012) Targeting inflammation in cardiovascular diseases. Still a neglected field? Cardiovasc Ther 30:e189–e197
45. Kassan M, Choi SK, Galan M et al (2013) Enhanced NF-kappaB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes. Diabetes 62:2078–2087
46. Halvorsen B, Otterdal K, Dahl TB et al (2008) Atherosclerotic plaque stability—what determines the fate of a plaque? Prog Cardiovasc Dis 51:183–194
47. Oh H, Ghosh S (2013) NF-kappaB: roles and regulation in different CD4(+) T cell subsets. Immunol Rev 252:41–51
48. Wu CC, Chen JS, Lu KC et al (2010) Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 411:700–704
49. Mahmoud F, Al-Ozairi E (2013) Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes. Dis Markers 35:235–241